- Front Page
- Why us
- Download & Publications
- Management team board
- Facts and figures
- General terms and conditions
- Environment, Health and Safety (EHS)
- Contact us
World Vaccine Congress
World Vaccine Congress
We at Novo Nordisk Pharmatech A/S are pleased to announce that we once again will be a part of the annual and the 17th World Vaccine Congress.
The 2017 World Vaccine Congress will be held in Washington D.C. April 10-12, and Novo Nordisk Pharmatech A/S will be present at booth # 54.
We hereby invite you to visit our booth and discover more about recombinant insulin for innovative biologics and pharmaceutical grade Quaternary ammonium compounds.
Novo Nordisk remain the best supplier of insulin for cell culture processes by excellence at every step of the supply chain, and we have more than 65 years experience in the biopharmaceutical and pharmaceutical industry.
We deliver a proven record of product Purity, Reliability and Consistency and can even tailor Quality products for future therapies.
Increase specific Influenza production with recombinant human insulin
The vaccine industry is challenged to produce large quantities of vaccines in a rapid and cost-effective way. Major changes to current bioprocesses are both difficult and very expensive to implement. Using HEK293 it has been demonstrated that addition of recombinant human insulin to commercially available chemically defined media, can be used as a supplement to increase VCD and specific viral yield.
*Data kindly supplied by Aziza Manceur, National Research Council Canada. Hemagglutinin (HA) assay is used for quantification of Influenza (H1N1). Insulin Human AF used in the experiments is supplied by Novo Nordisk Pharmatech. CD 293 media is trademark of Thermo Fisher Scientific.
If you want to learn more about our recombinant Insulin Human click here
We look forward to see you at our booth to a talk about why you should grow your cells with insulin from Novo Nordisk Pharmatech A/S.
"The World Vaccine Congress is now well-established as the must attend global vaccine event each year, where leaders of the industry come to discuss science and do business. Now in its 17th year, the event in 2017 will bring over 700 senior vaccine executives to learn, meet and form partnerships."